Tovo Cristiane Valle, Becker Smile Calisto da Costa, Almeida Paulo Roberto Lerias de, Galperim Bruno, Chaves Silvia
Hospital Nossa Senhora da Conceição, Porto Alegre, RS, Brazil.
Arq Gastroenterol. 2013 Jan-Mar;50(1):19-22. doi: 10.1590/s0004-28032013000100005.
The progression of liver fibrosis in patients coinfected by hepatitis C virus and human immunodeficiency virus (HCV/HIV) has been increasingly studied in the past decade. Studies made before the highly active antiretroviral therapy suggest that HIV can change the natural history of the HCV infection, leading to a faster progression of the liver fibrosis.
To evaluate and compare the fibrosis progression in two groups of patients (HCV/HIV coinfected and HCV monoinfected)
Seventy patients HCV monoinfected and 26 patients HCV/HIV coinfected who had not undertaken HCV treatment and were submitted to serial percutaneous liver biopsies were retrospectively evaluated. There was no difference in the fibrosis progression between the two groups.
The fibrosis grade evolution was not worse in the coinfected patients. The immunosuppression absence and the shortest time period between the biopsies in the coinfected group are possible explanations.
在过去十年中，对丙型肝炎病毒和人类免疫缺陷病毒合并感染（HCV/HIV）患者的肝纤维化进展进行了越来越多的研究。在高效抗逆转录病毒治疗之前进行的研究表明，HIV可改变HCV感染的自然病程，导致肝纤维化进展更快。
评估和比较两组患者（HCV/HIV合并感染和HCV单感染）的纤维化进展情况。
对70例未接受HCV治疗且接受了系列经皮肝活检的HCV单感染患者和26例HCV/HIV合并感染患者进行回顾性评估。两组之间的纤维化进展无差异。
合并感染患者的纤维化分级进展并不更差。合并感染组无免疫抑制以及活检之间的时间间隔最短可能是其原因。
